Trial Profile
A Multinational, Multicenter, Randomized, Double-blind, Study in Areas of High Pneumococcal Resistance Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Ketek Telithromycin Once Daily for 7 Days, or Zithromax Azithromycin Once Daily for 5 Days.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Telithromycin (Primary) ; Azithromycin
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Therapeutic Use
- 17 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 24 Oct 2006 Status change
- 29 Aug 2006 Status change